Lumara Health Inc.
http://www.lumarahealth.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lumara Health Inc.
Samsung Bioepis And Organon Get First High-Concentration Adalimumab Nod In US
Samsung Bioepis and Organon have broken new ground for Humira biosimilars in the US after receiving the first FDA approval for a higher-strength 100mg/ml adalimumab biosimilar.
Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
AbbVie’s Gonzalez Sounds Alarm On US Drug Price Negotiation Proposal
AbbVie posts solid quarter on strength of Skyrizi growth and continued US growth for Humira ahead of patent expiry. Imbruvica revenue continues to decline, however.
Keeping Track: Incyte’s Opzelura Earns First Vitiligo Claim; NDAs From Apellis, Acadia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Other Names / Subsidiaries
-
- Ethex Corporation
- K-V Pharmaceutical Company (KV Pharmaceutical)
- Ther-Rx Corporation